Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

Key PointsHims & Hers is a telehealth platform offering health and wellness solutions that has expanded into primary care and weight loss programs.Hims & Hers grew revenues 47% YoY to $246.6 million with an 83% gross profit margin turning the corner into GAAP profitability and raising its full year 2024 revenue guidance.The company grew its members by 48% YoY to 1.5 million subscribers.5 stocks we like better than Hims & Hers HealthHims & Hers Inc. NYSE: HIMS is a telehealth platform in the medical sector t ...

The shares of Hims & Hers Health (NYSE: HIMS), a direct-to-consumer telehealth company, have surged by more than 40% since the release of its Q4 earnings report and more than 50% since the start of the year.HIMS YTD stock price chart. Source: Google FinanceDespite being relatively unknown with a $2 billion valuation, the company has caught the interest of investors due to its impressive growth and improving financial performance.It might feel like a missed opportunity when news emerges of a stock already ga ...

Shares of direct-to-consumer telehealth business Hims & Hers Health (HIMS 0.61%) are up 30% since the company reported its Q4 earnings. The little-known $2 billion company is grabbing investors' attention with eye-popping growth and rapidly improving financials.It often feels like you've missed the boat when you sit there reading about another stock that got hot before you realized what was happening, but you haven't -- Hims & Hers is still a magnificent buy for long-term investors today.I'll detail why the ...

Hims & Hers Health, Inc. (HIMS) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.Analysts' growing optimism on the earnings prospects of this company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term ...

Key PointsHealthcare stocks are mainly known for massive growth once you add a bit of tech to them. Hims & Hers stock is the most attractive name in the space for all the right reasons.No competitor even comes close to the way analysts feel about it.5 stocks we like better than Ulta BeautyInvesting in healthcare stocks may not seem very exciting. This group of low-beta stocks serves as a defensive area of the consumer staples sector without much growth or activity. That is, of course, until technology comes ...

The New York Stock Exchange with a Hims & Hers Health, Inc banner is pictured as a person runs past in the Manhattan borough of New York City, New York, January 21, 2021.Hims & Hers Health, the online provider of treatments for erectile dysfunction and hair loss, had its best day on the stock market since its debut three years ago after quarterly results beat estimates and the company said it expects to deliver its first full year of profitability in 2024.Shares of Hims & Hers soared 32% to $13.48 as of Tue ...

Financial Data and Key Metrics - Revenue increased 65% year-over-year to $872 million in 2023 [17] - Subscribers grew 48% year-over-year to over 1.5 million by the end of 2023 [18] - Achieved first quarter of positive net income in Q4 2023, with net income of $1.2 million [43] - Adjusted EBITDA increased 68% quarter-over-quarter in Q4 2023 to almost $21 million [35] - Gross margins expanded to 83% in Q4 2023 and 82% for the full year, up almost 4 points year-over-year [34] Business Line Data and Key Metrics - Personalized offerings adopted by over 30% of subscribers by year-end 2023 [21] - Hers dermatology subscribers opted for personalized solutions more than 75% of the time, while nearly 100% of weight loss subscribers chose personalized treatments [25] - Over 85% of orders fulfilled through affiliated pharmacies by the end of 2023 [28] - Emerging categories like Hers dermatology, mental health, and weight loss are expected to each deliver over $100 million in revenue by 2025 [38] Market Data and Key Metrics - The company serves over 100 million individuals in the U.S. alone across its core specialties [20] - The company is targeting a long-term adjusted EBITDA margin of 20% to 30%, with expectations to reach low to mid-teens by 2027 [60] - Marketing as a percentage of revenue is expected to be in the mid-30s to low-40s by 2030 [60] Company Strategy and Industry Competition - The company is focused on expanding its portfolio of personalized solutions and improving the efficiency of affiliated pharmacies [55] - The strategy includes leveraging AI capabilities to inform new solutions and match users with the right treatments [37] - The company aims to bring tens of millions of users onto its platform, targeting mass-market pricing and convenience [42] - The company is confident in its ability to drive marketing leverage over time, with expectations of 1 to 3 points of marketing leverage per year starting in 2024 [64] Management Commentary on Operating Environment and Future Outlook - The company expects revenue in the range of $1.17 billion to $1.2 billion for 2024, representing a year-over-year increase of 34% to 38% [57] - Adjusted EBITDA for 2024 is expected to be between $100 million and $120 million, with an adjusted EBITDA margin of 9% at the midpoint [57] - The company is on track to achieve its 2025 targets of $1.2 billion in revenue and $100 million in EBITDA one year early [22] - The company is focused on removing barriers to treatment, such as lack of awareness, accessibility, and affordability, and expects personalization to be key in 2024 [27] Other Important Information - The company released its first-ever shareholder letter, available on its website [13] - The company uses non-GAAP financial measures, with reconciliation tables provided in the press release and shareholder letter [15] - The company ended 2023 with $221 million in cash and short-term investments, up over $41 million from the end of 2022 [55] Q&A Session Summary Question: Pricing Actions and Market Dynamics (George Hill, Deutsche Bank) - The company evaluates pricing actions based on experimentation and optimization of lifetime value analysis, rather than comparing to external factors [6][7] - The company is focused on leveraging scale and efficiency to pass value back to consumers over time [10] Question: Gross Margin Trajectory (Korinne Wolfmeyer, Piper Sandler) - Gross margins are expected to expand in 2024, with a long-term target of 75% [9] - The company is actively looking for ways to pass efficiencies back to consumers, but this will be a multiyear journey [10] Question: Emerging Categories and Marketing Spend (Allen Lutz, Bank of America) - The company is seeing strong adoption of personalized offerings in emerging categories like Hers dermatology and weight loss, with high retention rates [65] - Marketing spend is increasingly becoming semi-fixed, with expectations of greater leverage in 2024 and beyond [61] Question: Retention Rates and User Base (Daniel Grosslight, Citigroup) - The company is focused on maintaining a payback period of less than a year for customer acquisition costs [72] - Personalized solutions are driving higher retention and stickiness on the platform [87] Question: Weight Loss Product Offering (Glen Santangelo, Jefferies) - The company is offering personalized weight loss treatments at $70 per month, targeting underlying causes of weight gain [129] - The company expects GLP-1s to contribute meaningful growth in the coming years [130] Question: Free Cash Flow and Capital Deployment (Jailendra Singh, Truist Securities) - The company generated $47 million in free cash flow in 2023 and ended the year with $221 million in cash and short-term investments [142] - The company is focused on internal investments in affiliated pharmacies and personalized solutions, with potential for opportunistic M&A [136] Question: Gross Margin and Pricing Strategy (Michael Cherny, Leerink Partners) - The company is targeting a long-term gross margin in the mid-70s, with a focus on mass-market pricing and segmented offerings [166] - The company is running experiments to determine the optimal pricing mix to pass value back to consumers [153] Question: Subscriber Growth and Product Adoption (Ivan Feinseth, Tigress Financial Partners) - The company has seen rapid adoption of personalized treatments, with over 30% of subscribers on the platform using personalized offerings [170] - The company is focused on expanding its subscriber base and innovating with multi-condition treatments [159]

Shares of Hims & Hers Health Inc. rallied after hours on Monday, after the online wellness platform said 2024 would be its first year of positive net income and forecast first-quarter and full-year sales that were above expectations. That forecast came after the telehealth company — which offers health consultations and sells hair-loss, weight-loss and anxiety treatments, as well as sexual-health drugs like Viagra, through its Hims and Hers websites — reported its first-ever quarter of positive net income.H ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ____________ HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) | Delaware | 001-38986 | | 98-1482650 | | --- | --- | --- | ...